Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM)

Group 1 - AIM ImmunoTech Inc. is recognized as a fundamentally strong penny stock with a 'Buy' rating and a price target of $6.00, indicating a potential upside of nearly 133% [1] - The company presented positive progress from its Ampligen clinical program in pancreatic cancer at a recent symposium, highlighting its ongoing research efforts [2] - CEO Thomas K. Equels emphasized the potential of Ampligen for treating late-stage metastatic and locally advanced pancreatic cancer, addressing a significant unmet medical need [3] Group 2 - AIM ImmunoTech is an immuno-pharma company based in Ocala, Florida, focusing on developing solutions for various cancers, viral diseases, and immune deficiency disorders [3]